Meeting
2021 ASCO Annual Meeting
Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST.
Authors
Caicun Zhou
Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Caicun Zhou , Huijie Fan , Yongsheng Wang , Huijuan Wu , Nong Yang , KunYan Li , Xicheng Wang , Xintian Qin , Qitao Yu , Yong Fang , Min Tao , Xue Meng , Baohui Han , Xiaorong Dong , Bing Yan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04395677
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9066)
DOI
10.1200/JCO.2021.39.15_suppl.9066
Abstract #
9066
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase I, dose-escalation and expansion study of TQ-B3139, a novel ALK TKI, in Chinese ALK or ROS1 positive advanced non-small cell lung cancer (NSCLC).
First Author: Yuxiang Ma
Poster
2022 ASCO Annual Meeting
First-in-human phase I results of APG-2449, a novel FAK and third-generation ALK/ ROS1 tyrosine kinase inhibitor (TKI), in patients (pts) with second-generation TKI-resistant ALK/ROS1+ non–small cell lung cancer (NSCLC) or mesothelioma.
First Author: Hongyun Zhao
Poster
2016 ASCO Annual Meeting
Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).
First Author: Leora Horn
Poster
2015 ASCO Annual Meeting
Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC.
First Author: Alice Tsang Shaw